Skip to main content

Table 1 (abstract A48). Safety Summary

From: Proceedings of the 2019 Childhood Arthritis and Rheumatology Research Alliance (CARRA) Annual Scientific Meeting

 

2 years of abatacept treatment

6-month follow-up period

Day 113

Day 477

Day 645

Day 729

Day 85

Day 168

2–5-year-old cohort

Anti-GAD+

1

1

0

0

0

0

Anti-TPO+

0

0

0

0

0

0

6–17-year-old cohort

      

Anti-GAD+

0

0

0

1‡

0

0

Anti-TPO+†

0

3

1

1‡

0

1

  1. Values in table are number of patients. *Autoantibody positivity was defined as anti-GAD ≥5 IU/mL or anti-TPO ≥60 U/mL. TSH abnormalities were defined as >1.5x ULN, or if baseline was >ULN then >2x baseline value. †One patient had new-onset positive anti-TPO antibodies on Days 477, 645, 729 and Day 168 during the follow-up period. ‡The patients with positive anti-GAD and anti-TPO at Day 729 are different patients. GAD=glutamic acid decarboxylase; TPO=thyroid peroxidase; TSH=thyroid-stimulating hormone; ULN=upper limit of normal